Pfizer declined to comment for the story. "At some point, this will become a more traditional market - we'll look at what are the populations at risk, what value are we creating, and what are the number of products that serve that value. "We don't know what the market forces will be," Moderna President Stephen Hoge said in an interview last week. The World Health Organization has asked governments to hold off on booster shots until more people worldwide receive their initial doses. In addition, some scientists question whether there is enough evidence that boosters are needed, particularly for younger, healthy people.
The profit potential of booster shots may be limited by the number of competitors who enter the market. Some early data suggests that the Moderna vaccine, which delivers a higher dose at the outset, may be more durable than Pfizer’s shot, but more research is needed to determine whether that is influenced by the age or underlying health of the people vaccinated.Īs a result, it is far from clear how many people will need boosters, and how often. The vaccine makers say that evidence of waning antibody levels in vaccinated people after six months, as well as an increasing rate of breakthrough infections in countries hit by the Delta variant, support the need for booster shots. They eventually see the annual market settling at around $5 billion or higher, with additional drugmakers competing for those sales. Going forward, analysts have forecast revenue of over $6.6 billion for the Pfizer/BioNTech shot and $7.6 billion for Moderna in 2023, mostly from booster sales. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations. Pfizer, along with its German partner BioNTech, and Moderna have together locked up over $60 billion in sales of the shots just in 20.
0 kommentar(er)
